Bernd Bokemeyer

6.9k total citations
144 papers, 2.4k citations indexed

About

Bernd Bokemeyer is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Bernd Bokemeyer has authored 144 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 107 papers in Genetics, 90 papers in Epidemiology and 40 papers in Surgery. Recurrent topics in Bernd Bokemeyer's work include Inflammatory Bowel Disease (106 papers), Microscopic Colitis (77 papers) and Eosinophilic Esophagitis (29 papers). Bernd Bokemeyer is often cited by papers focused on Inflammatory Bowel Disease (106 papers), Microscopic Colitis (77 papers) and Eosinophilic Esophagitis (29 papers). Bernd Bokemeyer collaborates with scholars based in Germany, United States and United Kingdom. Bernd Bokemeyer's co-authors include Andreas Stallmach, Jürgen M. Stein, Stefan Schreiber, Axel Dignaß, Christoph Gasché, Daniel C. Baumgart, И. Л. Халиф, Philippe Marteau, Ivan V. Chopey and Tariq Iqbal and has published in prestigious journals such as Gastroenterology, PLoS ONE and The Journal of Urology.

In The Last Decade

Bernd Bokemeyer

128 papers receiving 2.3k citations

Peers

Countries citing papers authored by Bernd Bokemeyer

Since Specialization

Citations

This map shows the geographic impact of Bernd Bokemeyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernd Bokemeyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernd Bokemeyer more than expected).

Fields of papers citing papers by Bernd Bokemeyer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernd Bokemeyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernd Bokemeyer. The network helps show where Bernd Bokemeyer may publish in the future.

Co-authorship network of co-authors of Bernd Bokemeyer

This figure shows the co-authorship network connecting the top 25 collaborators of Bernd Bokemeyer. A scholar is included among the top collaborators of Bernd Bokemeyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernd Bokemeyer. Bernd Bokemeyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Six-Year Observation Data Reveal Reduction in Concomitant Steroid Overuse for Inflammatory Bowel Disease in Germany 2025 ·Inflammatory Bowel Diseases ·(unknown), Benjamin Friedrich, (unknown), Stefan Rath, (unknown), Bernd Bokemeyer	0
2	Burden of coeliac disease in Germany: real-world insights from a large retrospective health insurance claims database analysis 2025 ·Therapeutic Advances in Gastroenterology ·Bernd Bokemeyer, (unknown), (unknown), (unknown), (unknown), Detlef Schuppan	0
3	Comparative real-world effectiveness of ustekinumab versus anti-TNF in Crohn’s disease: 12-month maintenance phase results from the prospective, observational RUN-CD study using propensity score adjustment 2025 ·Journal of Crohn s and Colitis ·Bernd Bokemeyer, Sandra Plachta‐Danielzik, (unknown), Romina di Giuseppe, Herbert Deppe, Wolfgang Mohl, Niels Teich, (unknown), (unknown), Manfred von der Ohe, Annika Gauss, Raja Atreya, Thomas Krause, Irina Blumenstein, Petra Hartmann, Stefan Schreiber	1
4	Shared decision-making improves adherence to mesalamine in ulcerative colitis: A prospective, multicenter, non-interventional cohort study in Germany 2025 ·World Journal of Gastroenterology ·Wolfgang Kruis, (unknown), J Morgenstern, (unknown), (unknown), Bernd Bokemeyer	0
5	Switching within versus out of class following first-line TNFi failure in ulcerative colitis: real-world outcomes from a German claims data analysis 2024 ·Therapeutic Advances in Gastroenterology ·(unknown), (unknown), R Nissinen, (unknown), (unknown), (unknown), Jennifer Lee, (unknown), S. Mueller, Thomas Wilke, Bernd Bokemeyer	2
6	Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomised controlled trial in Germany (IBD_BIO‐ASSIST study) 2024 ·Alimentary Pharmacology & Therapeutics ·Bernd Bokemeyer, Sandra Plachta‐Danielzik, (unknown), (unknown), Eugen I. Urzica, Petra Hartmann, (unknown), (unknown), Stefan Schreiber, (unknown), (unknown), Angelika Hüppe, Tom Stargardt	2
7	Rates of clinical remission and inadequate response to advanced therapies among patients with ulcerative colitis in Germany 2023 ·International Journal of Colorectal Disease ·Bernd Bokemeyer, (unknown), (unknown), Ludger Rosin, Haridarshan Patel	7
8	Evaluation of a downstaging, bidirectional version of the Montreal classification of Crohn's disease: Analysis of 5‐year follow‐up data from the prospective BioCrohn study 2023 ·Alimentary Pharmacology & Therapeutics ·Bernd Bokemeyer, Sandra Plachta‐Danielzik, Romina di Giuseppe, Ulf Helwig, Niels Teich, Carsten Schmidt, Petra Hartmann, (unknown), Stefan Schreiber	2
9	OP36 Real-world evidence on comparative effectiveness of Ustekinumab vs anti-TNF in Crohn’s disease with propensity score adjustment: two-year maintenance phase results from the prospective observational RUN-CD study 2023 ·Journal of Crohn s and Colitis ·Bernd Bokemeyer, Sandra Plachta‐Danielzik, (unknown), Wolfgang Mohl, Niels Teich, (unknown), (unknown), (unknown), Annika Gauss, Raja Atreya, (unknown), Irina Blumenstein, (unknown), Petra Hartmann, (unknown), S Schreiber	1
10	Mapping from SIBDQ to EQ-5D-5L for patients with inflammatory bowel disease 2023 ·The European Journal of Health Economics ·(unknown), Bernd Bokemeyer, Tom Stargardt	4
11	P784 Real-world use and 6-month effectiveness of vedolizumab subcutaneous in IBD patients: results of the VEDO-IBD study 2023 ·Journal of Crohn s and Colitis ·Sandra Plachta‐Danielzik, Bernd Bokemeyer, (unknown), (unknown), (unknown), (unknown), (unknown), Elisabeth Schnoy, (unknown), (unknown), (unknown), Raja Atreya, Sören Franzenburg, Petra Hartmann, (unknown), Stefanie Schreiber	2
12	Real-world outcomes associated with switching to anti-TNFs versus other biologics in Crohn’s Disease patients: A retrospective analysis using German claims data 2022 ·Therapeutic Advances in Gastroenterology ·(unknown), Beatriz Antolin‐Fontes, (unknown), R Nissinen, (unknown), (unknown), Manuela Le Bars, Jennifer Lee, (unknown), Ulf Maywald, (unknown), Bernd Bokemeyer, Thomas Wilke, (unknown)	2
13	Practical advice for management of inflammatory bowel diseases patients during the COVID‐19 pandemic: World Endoscopy Organization Statement 2020 ·Digestive Endoscopy ·Helmut Neumann, Fabián Emura, Bernd Bokemeyer, Nalini M. Guda, Hisao Tajiri, Takayuki Matsumoto, David T. Rubin	8
14	[Inflammatory Bowel Disease Competence Network]. 2016 ·PubMed ·Stefan Schreiber, Heinz Hartmann, Wolfgang Kruis, Torsten Kucharzik, Jonas Mudter, Britta Siegmund, Andreas Stallmach, (unknown), (unknown), Bernd Bokemeyer	2
15	Kompetenznetz Darmerkrankungen 2016 ·Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz ·Stefan Schreiber, Heinz Hartmann, Wolfgang Kruis, Torsten Kucharzik, Jonas Mudter, Britta Siegmund, Andreas Stallmach, (unknown), (unknown), Bernd Bokemeyer	2
16	Segundo consenso europeo basado en evidencia sobre el diagnóstico y tratamiento de la colitis ulcerosa crónica idiopática. Parte 3: situaciones especiales (versión española) 2015 ·Revista de Gastroenterología de México ·Gert Van Assche, Axel Dignaß, Bernd Bokemeyer, Silvio Danese, Paolo Gionchetti, Gabriele Moser, Laurent Beaugerie, Fernando Gomollón, Winfried Häuser, Klaus Herrlinger, Bas Oldenburg, Julián Panés, Francisco Portela, Gerhard Rogler, Jürgen M. Stein, Herbert Tilg, Simon Travis, James O. Lindsay	2
17	Ferric Maltol Is Effective in Correcting Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease 2015 ·Inflammatory Bowel Diseases ·Christoph Gasché, Tariq Ahmad, Zsolt Tulassay, Daniel C. Baumgart, Bernd Bokemeyer, Carsten Büning, Stefanie Howaldt, Andreas Stallmach	96
18	Predictors for subsequent need for immunosuppressive therapy in early Crohn's disease 2011 ·Journal of Crohn s and Colitis ·Sandra Wenger, Susanna Nikolaus, Stefanie Howaldt, Bernd Bokemeyer, Andreas Sturm, J. Preiß, Alain Schoepfer, Andreas Stallmach, Carsten Schmidt	11
19	Kosten der Colitis ulcerosa – eine Kalkulation aus der Perspektive der Gesetzlichen Krankenversicherung 2010 ·DMW - Deutsche Medizinische Wochenschrift ·Anne Prenzler, Bernd Bokemeyer, Thomas Mittendorf, (unknown)	6
20	Health care costs and their predictors of inflammatory bowel diseases in Germany 2010 ·The European Journal of Health Economics ·Anne Prenzler, Bernd Bokemeyer, Johann‐Matthias Graf von der Schulenburg, Thomas Mittendorf	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact